Founding member of the Alliance for Building Better Medicine celebrates Virginia-based End-to-End Commercialization Project as another step toward protecting America's medicine cabinet. RICHMOND, Va., July 23, 2026 – Phlow Corp., a U.S.-based advanced...
Press Releases
Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer
RICHMOND, Va., July 22, 2026 – Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation's pharmaceutical supply chain and protecting America's medicine cabinet, today announced...
Phlow Corp. Appoints Tim Mayleben Chief Executive Officer as Co-Founder Dr. Eric Edwards Transitions to Chairman Emeritus and Strategic Advisor
PLANNED SUCCESSION TO SUPPORT NEXT PHASE OF GROWTH AS COMPANY ADVANCES U.S. PHARMACEUTICAL MANUFACTURING MISSION RICHMOND, Va., May 12, 2026 – Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today...
Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing
RICHMOND, Va., March 18, 2026 – Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s...
Fresenius Kabi and Phlow Corp. Announce First-Ever, End-to-End, U.S. Manufacturing Collaboration for Epinephrine Injection, USP
A Scalable Model for U.S. Pharmaceutical Security LAKE ZURICH, Ill. and RICHMOND, Va., February 9, 2026 – Fresenius Kabi and Phlow Corp. announced today a first-of-its-kind collaboration to onshore the manufacture of Epinephrine Injection, USP, an essential medicine...
Phlow and Enveda Partner to Advance AI-Driven Chemistry to Accelerate Domestic Pharmaceutical Development and Transform Drug Substance Manufacturing
RICHMOND, Va., January 14, 2026 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active Pharmaceutical Ingredient (API) manufacturing process development in...
Phlow Corp. CEO Outlines Path to Pharmaceutical Sovereignty in Testimony Before U.S. Senate
RICHMOND, Va., November 20, 2025 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), announced today that its Co-Founder and Chief Executive Officer, Dr. Eric S. Edwards, M.D., Ph.D., testified before the United...
Phlow Corp. Congratulates the Commonwealth of Virginia and the Virginia Innovation Partnership Corporation on a Historic Investment to Create the Nation’s Largest Workforce Development Center for Advanced Pharmaceutical Manufacturing
RICHMOND, Va., November 3, 2025 – Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), congratulates Governor Glenn Youngkin, the Virginia Innovation Partnership Corporation (VIPC), and several leading...
Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America
RICHMOND, Va., October 16, 2025 – Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food...
Phlow Appoints Tim M. Mayleben as Chairman of the Board, Building on Bold Leadership and Expanding America’s Medicine Manufacturing Future
RICHMOND, Va, Oct. 15, 2025 — Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced that current board member and former advisory board member Tim M. Mayleben has been appointed Chairman of the Board...